Tkacova R, Rankin F, Fitzgerald F S, Floras J S, Bradley T D
Sleep Research Laboratories of the Rehabilitation Institute of Toronto and Mount Sinai Hospital and the Department of Medicine of the University of Toronto, Toronto, Ontario, Canada.
Circulation. 1998 Nov 24;98(21):2269-75. doi: 10.1161/01.cir.98.21.2269.
The objectives of this study were to determine the effects of continuous positive airway pressure (CPAP) on blood pressure (BP) and systolic left ventricular transmural pressure (LVPtm) during sleep in congestive heart failure (CHF) patients with obstructive sleep apnea (OSA). In CHF patients with OSA, chronic nightly CPAP treatment abolishes OSA and improves left ventricular (LV) ejection fraction. We hypothesized that one mechanism whereby CPAP improves cardiac function in CHF patients with OSA is by lowering LV afterload during sleep.
Eight pharmacologically treated CHF patients with OSA were studied during overnight polysomnography. BP and esophageal pressure (Pes) (ie, intrathoracic pressure) were recorded before the onset of sleep and during stage 2 non-rapid eye movement sleep before, during, and after CPAP application. OSA was associated with an increase in systolic BP (from 120.4+/-7.8 to 131.8+/-10.6 mm Hg, P<0.05) and systolic LVPtm (from 124.4+/-7.7 to 137.2+/-10.8 mm Hg, P<0.05) from wakefulness to stage 2 sleep. CPAP alleviated OSA, improved oxyhemoglobin saturation, and reduced systolic BP in stage 2 sleep to 115.4+/-8.5 mm Hg (P<0.01), systolic LVPtm to 117.4+/-8.5 mm Hg (P<0.01), heart rate, Pes amplitude, and respiratory rate.
In CHF patients with OSA, LV afterload increases from wakefulness to stage 2 sleep. By alleviating OSA, CPAP reduces LV afterload and heart rate, unloads inspiratory muscles, and improves arterial oxygenation during stage 2 sleep. CPAP is a nonpharmacological means of further reducing afterload and heart rate during sleep in pharmacologically treated CHF patients with OSA.
本研究的目的是确定持续气道正压通气(CPAP)对伴有阻塞性睡眠呼吸暂停(OSA)的充血性心力衰竭(CHF)患者睡眠期间血压(BP)和左心室跨壁收缩压(LVPtm)的影响。在伴有OSA的CHF患者中,每晚进行慢性CPAP治疗可消除OSA并改善左心室(LV)射血分数。我们假设CPAP改善伴有OSA的CHF患者心脏功能的一种机制是在睡眠期间降低左心室后负荷。
对8例接受药物治疗的伴有OSA的CHF患者进行了整夜多导睡眠图研究。在睡眠开始前以及在应用CPAP之前、期间和之后的非快速眼动睡眠第2阶段记录血压和食管压力(Pes)(即胸内压)。OSA与收缩压从清醒到非快速眼动睡眠第2阶段升高(从120.4±7.8 mmHg升至131.8±10.6 mmHg,P<0.05)以及收缩期LVPtm升高(从124.4±7.7 mmHg升至137.2±10.8 mmHg,P<0.05)相关。CPAP减轻了OSA,改善了氧合血红蛋白饱和度,并将非快速眼动睡眠第2阶段的收缩压降至115.4±8.5 mmHg(P<0.01),收缩期LVPtm降至117.4±8.5 mmHg(P<0.01),同时降低了心率、Pes幅度和呼吸频率。
在伴有OSA的CHF患者中,左心室后负荷从清醒到非快速眼动睡眠第2阶段增加。通过减轻OSA,CPAP降低了左心室后负荷和心率,减轻了吸气肌负荷,并改善了非快速眼动睡眠第2阶段的动脉氧合。CPAP是在接受药物治疗的伴有OSA的CHF患者睡眠期间进一步降低后负荷和心率的一种非药物手段。